Moleculin Biotech, Inc. Skyrocketed

Moleculin Biotech, Inc. (MBRX:NASDAQ) rocketted at $1.27, a gain of 202.4%. On Thu, Feb 13, 2025, MBRX:NASDAQ touched a New 2-Week Intraday High of $3.65. The stock appeared on our News Catalysts scanner on Thu, Feb 13, 2025 at 03:26 PM in the 'PRIVATE PLACEMENT' category. From Thu, Jan 30, 2025, the stock recorded 10.00% Up Days and 9.09% Green Days
The stock spiked on Thu, Feb 13, 2025 at $3.65 with a volume of 100M+.
About Moleculin Biotech, Inc. (MBRX:NASDAQ)
Moleculin Biotech Inc is a preclinical stage pharmaceutical company. The company is engaged in the development of anti-cancer drug candidates. Its drug development technologies include liposomal Annamycin, WP1122 and WP1066.
Top 10 Gainers:
- Bolt Projects Holdings Inc Com (BSLK:NASDAQ), 303.28%
- Moleculin Biotech, Inc. (MBRX:NASDAQ), 202.38%
- Cloudastructure Inc. (CSAI:NASDAQ), 113.73%
- Alpha Modus Holdings Inc. (AMOD:NASDAQ), 97.81%
- Phoenix Motor Inc. (PEV:NASDAQ), 97.54%
- Dominari Holdings Inc Com (DOMH:NASDAQ), 89.23%
- MGO Global Inc. (MGOL:NASDAQ), 85.19%
- Edesa Biotech, Inc. (EDSA:NASDAQ), 74.73%
- Safe Pro Group Inc. (SPAI:NASDAQ), 65.76%
- INLIF LIMITED (INLF:NASDAQ), 51.68%